Refine
Year of publication
Has Fulltext
- yes (132)
Is part of the Bibliography
- no (132)
Keywords
- LHC (7)
- ALICE (3)
- ALICE experiment (3)
- Hadron-Hadron Scattering (3)
- pp collisions (3)
- Beauty production (2)
- Breast cancer (2)
- Diagnostik (2)
- Früherkennung (2)
- Heavy Ions (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Richtlinie (2)
- Single electrons (2)
- breast cancer (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- screening (2)
- 900 GeV (1)
- APP (1)
- Active middle ear implants (1)
- Atmospheric science (1)
- Auditory system (1)
- Australia (1)
- Bone conduction devices (1)
- Business strategy in drug development (1)
- C57BL/6J mice (1)
- C57BL/6N mice (1)
- CA1 (1)
- CABLE (1)
- COVID-19 (1)
- CVID (1)
- Cancer stem cells (1)
- Charm physics (1)
- Chocó rainforest (1)
- Climate change (1)
- Clinical variation (1)
- Cognitive impairment (1)
- Comparison with QCD (1)
- Consensus statement (1)
- Conservation biogeography (1)
- Deutsch (1)
- Digital breast tomosynthesis (DBT) (1)
- Digital mammography (1)
- Drug therapy (1)
- EBV (1)
- Ecuador (1)
- Elderly (1)
- EnKS 3D (1)
- European Society for Immunodeficiencies (ESID) (1)
- Femtoscopy (1)
- Frailty (1)
- GRACE (1)
- GRX1-roGFP2 (1)
- General practitioners (1)
- Genetic wildlife monitoring (1)
- German PID-NET registry (1)
- Glucose metabolism (1)
- HBT (1)
- Hadron production (1)
- Hair sampling (1)
- Health policy (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hypertension (1)
- IgG substitution therapy (1)
- Inclusive spectra (1)
- Insulin secretion (1)
- Intensity interferometry (1)
- Jets (1)
- KCGS (1)
- LTER (1)
- Long‐term ecosystem research (1)
- Lure sticks (1)
- MACE (1)
- Mid-rapidity (1)
- Mitochondrial shuttles (1)
- Mixed hearing loss (1)
- Morphologie (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- NMDA IgA/IgM antibodies (1)
- NMDA antibody (1)
- Noninvasive genetic sampling (1)
- North China Plain (1)
- Nuclear modification factor (1)
- Oldest-old (1)
- PCR-GLOBWB (1)
- PID prevalence (1)
- PYTHIA (1)
- Pancreatic islet (1)
- Parkinson disease (1)
- Pb–Pb (1)
- Population-based screening (1)
- Proton–proton (1)
- RT-qPCR (1)
- Recall rate (1)
- Redox-sensitive GFP (1)
- Rehabilitation (1)
- Relativistic heavy ion physics (1)
- Research infrastructure (1)
- SARS-CoV-2 (1)
- Satzanalyse (1)
- Semantik (1)
- Single muons (1)
- Site networks (1)
- Stimulus-secretion coupling (1)
- Surgery (1)
- Syntax (1)
- Technical data (1)
- Transverse momentum (1)
- W3 (1)
- WGHM (1)
- aboveground biomass (1)
- atherosclerosis (1)
- biodiversity (1)
- cardiovascular disease (1)
- chemogenomic set (1)
- chronosequence (1)
- data assimilation (1)
- dentate gyrus (1)
- diabetic macular edema (1)
- diclofenac (1)
- drug discovery (1)
- druggable genome (1)
- epigenetics (1)
- fluocinolone acetonide (1)
- groundwater storage (1)
- hemodialysis (1)
- immunostaining (1)
- in situ hybridization (1)
- kidney disease (1)
- kinase inhibitor (1)
- laser microdissection (1)
- meta-analysis (1)
- miRNA (1)
- microdosing (1)
- neutralizing antibodies (1)
- next-generation sequencing (1)
- oral enzyme combination (1)
- osteoarthritis (1)
- phenotypic screening (1)
- primary immunodeficiency (PID) (1)
- protein kinase (1)
- randomized controlled trial (1)
- reassembly (1)
- registry for primary immunodeficiency (1)
- resilience (1)
- resistance (1)
- small molecules (1)
- spectra (1)
- spike protein (1)
- trees (1)
- understudied kinase (1)
- variants of concern (1)
- western blotting (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (87)
- Frankfurt Institute for Advanced Studies (FIAS) (74)
- Informatik (74)
- Medizin (30)
- Biodiversität und Klima Forschungszentrum (BiK-F) (5)
- Senckenbergische Naturforschende Gesellschaft (5)
- Biowissenschaften (4)
- Biochemie und Chemie (3)
- Institut für Ökologie, Evolution und Diversität (3)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (2)
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1–25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0–88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%—subcutaneous; 29%—intravenous; 1%—unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
Ziele: Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) publiziert und koordiniert wurde, ist es, die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms zu optimieren.
Methoden: Der Aktualisierungsprozess der S3-Leitlinie aus 2012 basierte zum einen auf der Adaptation identifizierter Quellleitlinien und zum anderen auf Evidenzübersichten, die nach Entwicklung von PICO-(Patients/Interventions/Control/Outcome-)Fragen, systematischer Recherche in Literaturdatenbanken sowie Selektion und Bewertung der gefundenen Literatur angefertigt wurden. In den interdisziplinären Arbeitsgruppen wurden auf dieser Grundlage Vorschläge für Empfehlungen und Statements erarbeitet, die im Rahmen von strukturierten Konsensusverfahren modifiziert und graduiert wurden.
Empfehlungen: Der Teil 1 dieser Kurzversion der Leitlinie zeigt Empfehlungen zur Früherkennung, Diagnostik und Nachsorge des Mammakarzinoms: Der Stellenwert des Mammografie-Screenings wird in der aktualisierten Leitlinienversion bestätigt und bildet damit die Grundlage der Früherkennung. Neben den konventionellen Methoden der Karzinomdiagnostik wird die Computertomografie (CT) zum Staging bei höherem Rückfallrisiko empfohlen. Die Nachsorgekonzepte beinhalten Untersuchungsintervalle für die körperliche Untersuchung, Ultraschall und Mammografie, während weiterführende Gerätediagnostik und Tumormarkerbestimmungen bei der metastasierten Erkrankung Anwendung finden.
Purpose: The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast cancer.
Methods: The process of updating the S3 guideline dating from 2012 was based on the adaptation of identified source guidelines which were combined with reviews of evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions and the results of a systematic search of literature databases and the selection and evaluation of the identified literature. The interdisciplinary working groups took the identified materials as their starting point to develop recommendations and statements which were modified and graded in a structured consensus procedure.
Recommendations: Part 1 of this short version of the guideline presents recommendations for the screening, diagnosis and follow-up care of breast cancer. The importance of mammography for screening is confirmed in this updated version of the guideline and forms the basis for all screening. In addition to the conventional methods used to diagnose breast cancer, computed tomography (CT) is recommended for staging in women with a higher risk of recurrence. The follow-up concept includes suggested intervals between physical, ultrasound and mammography examinations, additional high-tech diagnostic procedures, and the determination of tumor markers for the evaluation of metastatic disease.
The inclusive charged particle transverse momentum distribution is measured in proton–proton collisions at s=900 GeV at the LHC using the ALICE detector. The measurement is performed in the central pseudorapidity region (|η|<0.8) over the transverse momentum range 0.15<pT<10 GeV/c. The correlation between transverse momentum and particle multiplicity is also studied. Results are presented for inelastic (INEL) and non-single-diffractive (NSD) events. The average transverse momentum for |η|<0.8 is 〈pT〉INEL=0.483±0.001 (stat.)±0.007 (syst.) GeV/c and 〈pT〉NSD=0.489±0.001 (stat.)±0.007 (syst.) GeV/c, respectively. The data exhibit a slightly larger 〈pT〉 than measurements in wider pseudorapidity intervals. The results are compared to simulations with the Monte Carlo event generators PYTHIA and PHOJET.
Suppression of high transverse momentum D mesons in central Pb-Pb collisions at √sNN = 2.76 TeV
(2012)
The production of the prompt charm mesons D0, D+, D∗+, and their antiparticles, was measured with the ALICE detector in Pb-Pb collisions at the LHC, at a centre-of-mass energy sNN−−−−√=2.76 TeV per nucleon--nucleon collision. The pT-differential production yields in the range 2<pT<16 GeV/c at central rapidity, |y|<0.5, were used to calculate the nuclear modification factor RAA with respect to a proton-proton reference obtained from the cross section measured at s√=7 TeV and scaled to s√=2.76 TeV. For the three meson species, RAA shows a suppression by a factor 3-4, for transverse momenta larger than 5 GeV/c in the 20% most central collisions. The suppression is reduced for peripheral collisions.
The transverse momentum (pT) distribution of primary charged particles is measured in minimum bias (non-single-diffractive) p-Pb collisions at sNN−−−√=5.02 TeV with the ALICE detector at the LHC. The pT spectra measured near central rapidity in the range 0.5<pT<20 GeV/c exhibit a weak pseudorapidity dependence. The nuclear modification factor RpPb is consistent with unity for pT above 2 GeV/c. This measurement indicates that the strong suppression of hadron production at high pT observed in Pb-Pb collisions at the LHC is not due to an initial-state effect. The measurement is compared to theoretical calculations.
Measurement of charm production at central rapidity in proton-proton collisions at √s = 2.76 TeV
(2012)
The pT-differential production cross sections of the prompt (B feed-down subtracted) charmed mesons D0, D+, and D∗+ in the rapidity range |y|<0.5, and for transverse momentum 1<pT<12 GeV/c, were measured in proton-proton collisions at s√=2.76 TeV with the ALICE detector at the Large Hadron Collider. The analysis exploited the hadronic decays D0→Kπ, D+→Kππ, D∗+→D0π, and their charge conjugates, and was performed on a Lint=1.1 nb−1 event sample collected in 2011 with a minimum-bias trigger. The total charm production cross section at s√=2.76 TeV and at 7 TeV was evaluated by extrapolating to the full phase space the pT-differential production cross sections at s√=2.76 TeV and our previous measurements at s√=7 TeV. The results were compared to existing measurements and to perturbative-QCD calculations. The fraction of cdbar D mesons produced in a vector state was also determined.
The ALICE Zero Degree Calorimeter system (ZDC) is composed of two identical sets of calorimeters, placed at opposite sides with respect to the interaction point, 114 meters away from it, complemented by two small forward electromagnetic calorimeters (ZEM). Each set of detectors consists of a neutron (ZN) and a proton (ZP) ZDC. They are placed at zero degrees with respect to the LHC axis and allow to detect particles emitted close to beam direction, in particular neutrons and protons emerging from hadronic heavy-ion collisions (spectator nucleons) and those emitted from electromagnetic processes. For neutrons emitted by these two processes, the ZN calorimeters have nearly 100% acceptance.
During the √sNN = 2.76 TeV Pb-Pb data-taking, the ALICE Collaboration studied forward neutron emission with a dedicated trigger, requiring a minimum energy deposition in at least one of the two ZN. By exploiting also the information of the two ZEM calorimeters it has been possible to separate the contributions of electromagnetic and hadronic processes and to study single neutron vs. multiple neutron emission.
The measured cross sections of single and mutual electromagnetic dissociation of Pb nuclei at √sNN = 2.76 TeV, with neutron emission, are σsingle EMD = 187:4 ± 0.2 (stat.)−11.2+13.2 (syst.) b and σmutual EMD = 5.7 ± 0.1 (stat.) ±0.4 (syst.) b, respectively [1]. This is the first measurement of electromagnetic dissociation of 208Pb nuclei at the LHC energies, allowing a test of electromagnetic dissociation theory in a new energy regime. The experimental results are compared to the predictions from a relativistic electromagnetic dissociation model.
This paper reports on Monte Carlo simulation results for future measurements of the moduli of time-like proton electromagnetic form factors, |GE | and |GM|, using the ¯pp → μ+μ− reaction at PANDA (FAIR). The electromagnetic form factors are fundamental quantities parameterizing the electric and magnetic structure of hadrons. This work estimates the statistical and total accuracy with which the form factors can be measured at PANDA, using an analysis of simulated data within the PandaRoot software framework. The most crucial background channel is ¯pp → π+π−,due to the very similar behavior of muons and pions in the detector. The suppression factors are evaluated for this and all other relevant background channels at different values of antiproton beam momentum. The signal/background separation is based on a multivariate analysis, using the Boosted Decision Trees method. An expected background subtraction is included in this study, based on realistic angular distribuations of the background contribution. Systematic uncertainties are considered and the relative total uncertainties of the form factor measurements are presented.
The ALICE experiment has measured the inclusive J/ψ production in Pb-Pb collisions at sNN−−−√=2.76 TeV down to zero transverse momentum in the rapidity range 2.5<y<4. A suppression of the inclusive J/ψ yield in Pb-Pb is observed with respect to the one measured in pp collisions scaled by the number of binary nucleon-nucleon collisions. The nuclear modification factor, integrated over the 0-80% most central collisions, is 0.545±0.032(stat.)±0.083(syst.) and does not exhibit a significant dependence on the collision centrality. These features appear significantly different from measurements at lower collision energies. Models including J/ψ production from charm quarks in a deconfined partonic phase can describe our data.